Table 6.
BCR | Metastasis | PCSM | ||||
---|---|---|---|---|---|---|
OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | |
KLK3 | 0.85 (0.69–1.06) | 0.154 | 0.72 (0.57–0.91) | 0.007 | 0.6 (0.46–0.78) | < 0.001 |
PSA | 1 (0.99–1.02) | 0.983 | 1.01 (1–1.03) | 0.205 | 0.6 (0.46–0.78) | 0.327 |
pT stage | ||||||
pT2 | Ref (-) | Ref (-) | Ref (-) | |||
pT3a | 1.79 (1.2–2.66) | 0.004 | 1.53 (0.95–2.46) | 0.079 | 0.6 (0.46–0.78) | 0.619 |
pT3b | 3.48 (2.19–5.6) | < 0.001 | 3.92 (2.42–6.41) | < 0.001 | 1.01 (0.99–1.02) | 0.014 |
GGG | ||||||
GGG = < 2 | Ref (-) | Ref (-) | Ref (-) | |||
GGG3 | 1.13 (0.71–1.82) | 0.605 | 2.91 (1.69–5.06) | < 0.001 | 0.6 (0.46–0.78) | 0.01 |
GGG4 | 1.18 (0.68–2.05) | 0.561 | 3.88 (2.1–7.18) | < 0.001 | 1.01 (0.99–1.02) | 0.005 |
GGG5 | 2.2 (1.39–3.5) | 0.001 | 6.86 (4.22–11.36) | < 0.001 | 1.18 (0.62–2.24) | < 0.001 |
Abbreviations: BCR (Biochemical recurrence); PCSM (Prostate cancer specific mortality).